Perrigo Drug's Pricing Way Off, Expert Says In $163M Tax Trial
The $466 million an Israeli subsidiary of Irish drugmaker Perrigo Co. earned from sales of a heartburn medication "in no way can possibly comply" with transfer pricing law, an economist said Monday during the...To view the full article, register now.
Already a subscriber? Click here to view full article